Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia

Blood

Volumn 87, Issue 4, 1996, Pages 1249-1254

  Robinson, Nanette ^b   Sanders, Jean E ^b   Benyunes, Mark C ^b   Beach, Kathy ^b   Lindgren, Catherine ^b   Thompson, John A ^b   Appelbaum, Frederick R ^b   Fefer, Alexander ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ACUTE LEUKEMIA; ACUTE RESPIRATORY FAILURE; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HYPOTENSION; IMMUNOPHENOTYPING; LUNG INFILTRATE; LYMPHOCYTOSIS; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; WHOLE BODY RADIATION;

EID: 0030019977     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.4.1249.bloodjournal8741249     Document Type: Article

References (44)

1. Sanders JE, Flournoy N, Thomas ED: Marrow transplant experience in children with acute lymphoblastic leukemia: An analysis of factors associated with survival, relapse, and graft vs. host disease. Med Pediatr Oncol 13:165, 1985
2. Long GD, Blume KG: Allogeneic bone marrow transplantation for acute myelogenous leukemia, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, MA, Blackwell, 1994, p 607
3. Clift R, Buckner C, Appelbaum F, Bearman S, Petersen F, Fisher L, Anasetti C, Beatty P, Bensinger W, Doney K, Hill R, McDonald G, Martin P, Sanders J, Singer J, Stewart P, Sullivan K, Witherspoon R, Storb R, Hansen J, Thomas E: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 76:1867, 1990
4. Aurer I, Gale RP: Are new conditioning regimens for transplants in acute myelogenous leukemia better? Bone Marrow Transplant 7:255, 1991
5. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068, 1979
6. Fefer A: Graft-versus-tumor responses: Adoptive cellular therapy in bone marrow transplantation, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, MA, Blackwell,1994, p 231
7. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, KoIb H-J, Rimm AA, Ringdén, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
8. Antin JH: Graft-versus-leukemia: No longer an epiphenomenon. Blood 82:2273, 1993
9. Sznol M, Parkinson DR: Interleukin-2 in therapy of hematologic malignancies. Blood 83:2020, 1994
10. Sykes M, Romick ML, Sachs DH: Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 87:5633, 1990
11. + cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 83:2560, 1994
12. Malovsky M, Brenner MK, Hunt R, Rastan S, Dore C, Brown S, North ME, Asherson GL, Prentice HG, Medawar PB: T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol 103:476, 1986
13. Weiss L, Reich S, Slavin S: Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest 10:19, 1992
14. Truitt RL, Johnson BD: Graft-versus-host disease and the graft-versus-leukemia effect: Lessons from allogeneic bone marrow transplantation, in Spitzer TR, Mazumder A (eds): Immunotherapy and Bone Marrow Transplantation. Armonk, NY, Futura, 1995, p 1
15. Antin JH, Ferrara J: Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964, 1992
16. Ferrara J, Deeg HJ: Graft-versus-host disease. N Engl J Med 324:667, 1991
17. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H: Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 327:1613, 1992
18. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg JH, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Flournoy N, Storb R, Thomas ED: Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66:664, 1985
19. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringdén O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2121, 1991
20. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin JE, Gluckman E, Hoffman RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann Intern Med 108:806, 1988
21. Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964, 1994
22. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295, 1974
23. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louis AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688, 1995
24. Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A: Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 77:2561, 1991
25. Gottlieb DJ, Brenner MK, Heslop HE, Bianchi ACM, Bello-Fernandez C, Mehta AB, Newland AC, Galazka AR, Scott EM, Hoffbrand AV, Prentice HG: A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: Applicability to the elimination of minimal residual disease. Br J Cancer 60:610, 1989
26. Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A: Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 12:159, 1993
27. Blaise D, Olive D, Stoppa AM, Viens P, Pourrea C, Lopez M, Attal M, Jasmin C, Monges G, Mawas C, Mannoni P, Palmer P, Franks C, Philip T, Maraninchi D: Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 76:1092, 1990
28. Higuchi CM, Thompson JA, Cox T, Lindgren CG, Buckner CD, Fefer A: Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematologic malignancies. Cancer Res 49:5509, 1989
29. Foa R, Fierro MT, Tosti S, Meloni G, Gavosto F, Mandelli F: Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leuk Lymphoma 1:113, 1989
30. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F: Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84:2158, 1994
31. Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa AM, Reiffers J, Gratecos N, Bertau-Perez P, Mannoni P, Mawas C, Hercend T, Sebahoun G, Carcassonne Y: High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78:2182, 1991
32. Fefer A, Benyunes MC, Massumoto C, Higuchi C, York A, Buckner CD, Thompson JA: Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 20:41, 1993 (suppl 9)
33. Hamon MD, Prentice HG, Gottlieb DJ, Macdonald ID, Cunningham JM, Smith OP, Gilmore M, Gandhi L, Collis C: Immunotherapy with interleukin 2 after ABMT in AML. Bone Marrow Transplant 11:399, 1993
34. Favrot MC, Floret D, Negrier S, Cochat P, Bouffet E, Dacheng Z, Franks CR, Bijman T, Brunat-Metigny M, Philip I, Philip T: Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant 4:499, 1989
35. Butturini A, Bonilauri E, Izzi G, Croci G, Franchi F, Santucci MA, Tondelli MT, Scanderbeg AC: Therapy of advanced acute myeloblastic leukemia with cytarabine and interleukin 2. Leuk Res 15:759, 1991
36. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D, Fefer A. Influence of schedule of interleukin-2 administration on therapy with interleukin-2 and lymphokine activated killer cells. Cancer Res 49:235, 1989
37. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A: Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 6:669, 1988
38. Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A: Immunotherapy with interleukin-2 with or without lymphokine activated killer cells after autologous bone marrow transplantation for malignant lymphoma: A feasibility trial. Bone Marrow Transplant (in press)
39. Sanders JE, Thomas ED, Buckner CD, Flournoy N, Stewart PS, Clift RA, Lum L, Bensinger WI, Storb R, Appelbaum FR, Sullivan KM: Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: An update. Blood 66:460, 1985
40. Locatelli F, Uderzo C, Dini G, Zecca M, Arcese W, Messina C, Andolina M, Miniero R, Porta F, Rovelli A, Pession A, Rondelli R, Paolucci P: Graft-versus-host disease in children: The AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant 12:627, 1993
41. Eisner MD, August CS: Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 15:663, 1995
42. Keever CA, Small TN, Flomenberg N, Heller G, Pekle K, Black P, Pecora A, Gillio A, Kernan NA, O'Reilly RJ: Immune reconstitution following bone marrow transplantation: Comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 73:1340, 1989
43. Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Prentice HG, Brenner MK: Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 73:1351, 1989
44. Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK: Effects of recombinant interleukin-2 administration on cytokine function following high-dose chemo-radiotherapy for hematologic malignancy. Blood 74:2335, 1989